RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
11 Jul, 2022 | 11:49h | UTCZanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)